KemPharm, Inc. Advances KP201 Clinical and Commercial Program With...

... its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute moderate to ...

http://www.biospace.com/news_story.aspx?StoryID=293518&full=1